The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
about
Clinical use of pharmacogenomic tests in 2009Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineThiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population.Advances in the development of genetic markers for the diagnosis of disease and drug response.Pharmacogenetics and pharmacogenomics of anticancer agents.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacogenomic considerations for immunosuppressive therapy.Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.Pharmacogenomic considerations in drug delivery.Pharmacogenetics in Ghana: reviewing the evidence.Using multiple drug exposure levels to optimize power in pharmacogenetic trials.Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population.Pharmacogenetics goes genomic.Cancer pharmacogenetics.Pharmacogenetic approaches to rheumatoid arthritis.Cytochrome P450 3A polymorphisms and immunosuppressive drugs.HIV resistance testing in the USA--a model for the application of pharmacogenomics in the clinical setting.Drug repositioning for personalized medicine.Genetic susceptibility to iatrogenic malignancy.Individualization of mycophenolate mofetil dose in renal transplant recipients.Pharmacogenetics approach to therapeutics.The role of pharmacogenetics in cancer therapeutics.Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.Overview of the pharmacoeconomics of pharmacogenetics.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.Impact of pharmacogenomics on clinical practice in oncology.Routine pharmacogenetic testing in clinical practice: dream or reality?Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.Pharmacogenetics of Crohn's disease.A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicityThe increasing complexity of mercaptopurine pharmacogenomics.Pharmacogenetics: implementing personalized medicine.Meta-analysis of the impact of thioprine S-methyltransferase polymorphisms on the tolerable 6-mercaptopurine dose considering initial dose and ethnic difference.Immunotherapy of neuromyelitis optica.Implementation of TPMT testing.Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnostics.
P2860
Q24657536-0D9F85A6-01B7-4504-A2F4-46B3ED54F1CDQ28082746-1C52F919-AA25-4572-A0B7-7CAAFA8A0F89Q33394134-B8739913-54E5-4FFD-BD70-B8ECD97F22A5Q34775319-4BC2561B-D8D5-41CD-911C-4BFB3C9CEAA3Q34793050-1E665DFD-542D-42B4-B118-EDD9C7F3ECE8Q34884611-539EF3A1-9DD2-4E32-9B53-F52AD8880266Q35030489-727725DB-F4DB-4551-8EC2-849E507E6BC1Q35070838-F3DDA271-FA74-49F5-A184-0BEFA0E19DF9Q35116105-F71E0D7F-2213-40B0-A95D-1C1C97100125Q35127786-3A0E1144-9BDA-49A7-9F9B-01FD3FDA4D71Q35164676-9897064D-3F7F-48E6-AF9D-3856552AC58EQ35172002-BFC0F515-C3C0-4CE6-9269-E35ADD2802CDQ35210791-59AD67D7-B9C7-4006-BDB0-50F6E42947D3Q35225364-D43B71DD-56F6-46D6-95E7-C7771E5E99BCQ35590351-9669496F-3A7A-4BA2-A7D1-B3A0747575E0Q35622437-F27DE30A-567B-4B5B-BF57-F3990E389359Q35834289-1F2414FC-1F72-40C5-A4F6-50AD3E955137Q36050572-C84EC1F2-3F1F-4F49-9AD0-DE6A8ADBB29BQ36120838-2497393C-B95D-46D1-B1C7-8EC8E93844B3Q36245193-D1CE1801-7DBE-4A6D-AC59-A6882ED4AFFDQ36249238-96F89D9B-F281-4B58-A8B0-31542FC88139Q36407345-7EF734FE-282C-412D-BBDD-692BF59223FBQ36478845-22F06A5E-554F-4B29-AE24-7D3114D752E4Q36536674-41C1F2DD-5973-4658-9234-A6CFA8E61B22Q36554709-49A4D8A4-236B-4CE0-B324-4CFABB807787Q36690248-A5F2374C-6B55-4E92-B1FB-AE4D406DE2B8Q36709301-D2476FDD-822C-4B6E-9B63-A2D384B76B9DQ36761673-95115DFF-C862-416C-ABA4-BEE9DCEECB49Q36775605-071CDF75-D577-40B8-8900-2B19EE05B1EAQ36989859-531FF6F6-31C6-4677-AEB9-235FF035734FQ37171402-83FAA78A-85FA-4CD4-9798-393D91584717Q37176567-D0CA100A-B2B4-4CAE-B1F4-2F211259132FQ37205946-5AD76F76-A0CB-4C97-BD2B-8156AFF38909Q37371303-AEFF47B1-3484-477A-8E4F-13055EF92FE3Q37371590-157BBBBB-E079-49C5-ABF0-B50F58615821Q37430384-0EC3A17A-82F6-4D96-BFC9-16D198CE02E2Q37446511-05E8555B-70E3-41D5-BB18-C95783A9A462Q37456974-968860BE-3D9F-40D2-B00D-0FD9854D0E28Q37678056-8B063CD6-9C82-4217-9C2F-F0D3ABA7E3D5Q37755229-7048BF01-058C-45D0-A1F8-5665F7E6C10D
P2860
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@ast
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@en
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@nl
type
label
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@ast
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@en
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@nl
prefLabel
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@ast
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@en
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@nl
P2860
P356
P1433
P1476
The thiopurine S-methyltransfe ...... for clinical pharmacogenomics.
@en
P2093
Chokkalingam Siva
Howard L McLeod
P2860
P356
10.1517/14622416.3.1.89
P577
2002-01-01T00:00:00Z